Float Short %

9.8

Margin Of Safety %

-24

Put/Call OI Ratio

0.14

EPS Next Q Diff

-0.06

EPS Last/This Y

-6.45

EPS This/Next Y

0.95

Price

57.53

Target Price

69.08

Analyst Recom

1.17

Performance Q

25.2

Relative Volume

0.59

Beta

2.22

Ticker: PTGX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-25	PTGX	55.17	0.25	0.00	3157
2025-07-28	PTGX	56.28	0.25	0.15	3157
2025-07-29	PTGX	55.01	0.25	0.15	3157
2025-07-30	PTGX	54.55	0.25	5.50	3169
2025-07-31	PTGX	53.85	0.26	0.25	3208
2025-08-01	PTGX	53.8	0.26	1.00	3216
2025-08-04	PTGX	53.86	0.26	0.15	3217
2025-08-05	PTGX	53.89	0.25	2.00	3490
2025-08-06	PTGX	53.8	0.25	2.00	3490
2025-08-07	PTGX	50.92	0.25	1.50	3498
2025-08-08	PTGX	51.11	0.25	0.08	3513
2025-08-11	PTGX	53.78	0.25	0.06	3513
2025-08-12	PTGX	54.54	0.25	0.00	3511
2025-08-13	PTGX	56.77	0.25	0.00	3511
2025-08-14	PTGX	54.97	0.24	0.00	3613
2025-08-15	PTGX	56.09	0.24	0.05	3621
2025-08-18	PTGX	56.17	0.14	0.01	2981
2025-08-19	PTGX	56.25	0.14	0.20	2999
2025-08-20	PTGX	56.21	0.14	0.00	3001
2025-08-21	PTGX	55.99	0.14	0.00	3002
2025-08-22	PTGX	57.48	0.14	0.00	3004
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-25	PTGX	55.15	-5.0	-	-1.65
2025-07-28	PTGX	56.20	-5.0	-	-1.65
2025-07-29	PTGX	55.01	-5.0	-	-1.65
2025-07-30	PTGX	54.62	-5.0	-	-1.65
2025-07-31	PTGX	53.86	-5.0	-	-1.65
2025-08-01	PTGX	53.83	-5.0	-	-1.65
2025-08-04	PTGX	53.83	-5.0	-	-1.65
2025-08-05	PTGX	53.90	-5.0	-	-1.65
2025-08-06	PTGX	53.89	-5.0	-	-1.65
2025-08-07	PTGX	50.96	-5.0	-	-1.65
2025-08-08	PTGX	51.07	-5.0	-	-1.65
2025-08-11	PTGX	53.79	-14.3	-	-1.84
2025-08-12	PTGX	54.52	-14.1	-	-1.98
2025-08-13	PTGX	56.72	-14.1	-	-1.98
2025-08-14	PTGX	54.99	-14.1	-	-1.98
2025-08-15	PTGX	56.08	-14.1	-	-1.98
2025-08-18	PTGX	56.19	-14.1	-	-1.98
2025-08-19	PTGX	56.25	-14.1	-	-1.98
2025-08-20	PTGX	56.24	-14.1	-	-1.98
2025-08-21	PTGX	56.04	-14.1	-	-1.98
2025-08-22	PTGX	57.53	-14.1	-	-1.98
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-25	PTGX	-3.69	-0.39	10.60
2025-07-28	PTGX	-3.69	-0.42	10.59
2025-07-29	PTGX	-3.98	-0.42	10.59
2025-07-30	PTGX	-3.98	-0.42	10.59
2025-07-31	PTGX	-3.98	-0.42	10.59
2025-08-01	PTGX	-4.00	-0.42	10.59
2025-08-04	PTGX	-4.00	-0.21	10.59
2025-08-05	PTGX	-4.00	-0.21	10.59
2025-08-06	PTGX	-4.00	-0.21	10.59
2025-08-07	PTGX	-4.00	-0.21	10.59
2025-08-08	PTGX	-4.00	-0.21	10.59
2025-08-11	PTGX	-3.98	-0.37	10.55
2025-08-12	PTGX	-3.98	-0.37	9.82
2025-08-13	PTGX	-3.98	-0.37	9.82
2025-08-14	PTGX	-3.98	-0.37	9.82
2025-08-15	PTGX	-3.98	-0.37	9.82
2025-08-18	PTGX	-3.98	0.23	9.80
2025-08-19	PTGX	-4.12	0.23	9.80
2025-08-20	PTGX	-4.12	0.23	9.80
2025-08-21	PTGX	-3.98	0.23	9.80
2025-08-22	PTGX	-3.98	0.23	9.80
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.55

Avg. EPS Est. Current Quarter

-0.62

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-3.98

Institutional Transactions

0.23

Beta

2.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

5.1

Max Drawdown 5-Year %

-85.8

Target Price

69.08

P/E

80.66

Forward P/E

PEG

P/S

17.09

P/B

5.34

P/Free Cash Flow

96.39

EPS

0.71

Average EPS Est. Cur. Y

-1.98

EPS Next Y. (Est.)

-1.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.88

Relative Volume

0.59

Return on Equity vs Sector %

-16.9

Return on Equity vs Industry %

-4

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.33

EBIT Estimation

Protagonist Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 130

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today

news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance

stock history PTGX – Protagonist Therapeutics Inc invest stock market

stock prices PTGX premarket after hours

ticker PTGX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PTGX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y